Volume | 1,317,018 |
|
|||||
News | (1) | ||||||
Day High | 12.39 | Low High |
|||||
Day Low | 12.02 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
NovoCure Ltd | NVCR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
12.09 | 12.02 | 12.39 | 12.34 | 12.055 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
16,630 | 1,317,018 | $ 12.25 | $ 16,127,798 | - | 10.87 - 83.60 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:46:58 | formt | 100 | $ 12.38 | USD |
NovoCure Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.32B | 107.09M | - | 509.34M | -207.04M | -1.93 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
NovoCure News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NVCR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 12.40 | 12.46 | 11.70 | 12.02 | 1,050,152 | -0.02 | -0.16% |
1 Month | 14.78 | 16.05 | 11.70 | 14.12 | 1,785,868 | -2.40 | -16.24% |
3 Months | 14.09 | 18.04 | 11.70 | 14.62 | 1,291,696 | -1.71 | -12.14% |
6 Months | 14.14 | 18.04 | 10.87 | 13.91 | 1,367,460 | -1.76 | -12.45% |
1 Year | 62.93 | 83.60 | 10.87 | 25.15 | 1,512,045 | -50.55 | -80.33% |
3 Years | 208.82 | 232.76 | 10.87 | 60.86 | 943,784 | -196.44 | -94.07% |
5 Years | 45.09 | 232.76 | 10.87 | 76.50 | 932,953 | -32.71 | -72.54% |
NovoCure Description
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States. |